×

Transition therapy: tackling the ecology of tumor phenotypic plasticity. (English) Zbl 1481.92056

Summary: Phenotypic switching in cancer cells has been found to be present across tumor types. Recent studies on glioblastoma report a remarkably common architecture of four well-defined phenotypes coexisting within high levels of intra-tumor genetic heterogeneity. Similar dynamics have been shown to occur in breast cancer and melanoma and are likely to be found across cancer types. Given the adaptive potential of phenotypic switching (PHS) strategies, understanding how it drives tumor evolution and therapy resistance is a major priority. Here we present a mathematical framework uncovering the ecological dynamics behind PHS. The model is able to reproduce experimental results, and mathematical conditions for cancer progression reveal PHS-specific features of tumors with direct consequences on therapy resistance. In particular, our model reveals a threshold for the resistant-to-sensitive phenotype transition rate, below which any cytotoxic or switch-inhibition therapy is likely to fail. The model is able to capture therapeutic success thresholds for cancers where nonlinear growth dynamics or larger PHS architectures are in place, such as glioblastoma or melanoma. By doing so, the model presents a novel set of conditions for the success of combination therapies able to target replication and phenotypic transitions at once. Following our results, we discuss transition therapy as a novel scheme to target not only combined cytotoxicity but also the rates of phenotypic switching.

MSC:

92C50 Medical applications (general)
PDFBibTeX XMLCite
Full Text: DOI

References:

[1] Alarcón, T.; Sardanyés, J.; Guillamon, A.; Menendez, JA, Bivalent chromatin as a therapeutic target in cancer: an in silico predictive approach for combining epigenetic drugs, PLOS Comput Biol, 17, 6, e1008408 (2021)
[2] Amirouchene-Angelozzi, N.; Swanton, C.; Bardelli, A., Tumor evolution as a therapeutic target, Cancer Discov, 7, 805-817 (2017)
[3] Balaban, NQ; Merrin, J.; Chait, R.; Kowalik, L.; Leibler, S., Bacterial persistence as a phenotypic switch, Science, 305, 1622-1625 (2004)
[4] Balalszi, G.; Oudenaarden, AV; Collins, JJ, Cellular decision making and biological noise: from microbes to mammals, Cell, 144, 910-925 (2011) · doi:10.1016/j.cell.2011.01.030
[5] Basanta, D.; Anderson, AR, Exploiting ecological principles to better understand cancer progression and treatment, Interface Focus, 3, 4, 20130020 (2013)
[6] Basanta, D.; Gatenby, RA; Anderson, AR, Exploiting evolution to treat drug resistance: combination therapy and the double bind, Mol Pharm, 9, 4, 914-921 (2012)
[7] Benzekry, S.; Lamont, C.; Beheshti, A.; Tracz, A.; Ebos, JM; Hlatky, L.; Hahnfeldt, P., Classical mathematical models for description and prediction of experimental tumor growth, PLoS Computat Biol, 10, 8, e1003800 (2014)
[8] Berrieman, HK; Lind, MJ; Cawkwell, L., Do beta-tubulin mutations have a role in resistance to chemotherapy?, Lancet Oncol, 5, 3, 158-164 (2004)
[9] Bozic, I., Evolutionary dynamics of cancer in response to targeted combination therapy, eLife, 2, e00747 (2013) · doi:10.7554/eLife.00747
[10] Brock, A.; Chang, H.; Huang, S., Non-genetic heterogeneity-a mutation-independent driving force for the somatic evolution of tumours, Nat Rev Genet, 10, 336-342 (2009)
[11] Celià-Terrassa, T.; Bastian, C.; Liu, DD; Ell, B.; Aiello, NM; Wei, Y.; Kang, Y., Hysteresis control of epithelial-mesenchymal transition dynamics conveys a distinct program with enhanced metastatic ability, Nat commun, 9, 1, 1-12 (2018)
[12] de Thé, H., Differentiation therapy revisited, Nat Rev Can, 18, 117 (2018)
[13] Dean, M.; Fojo, T.; Bates, S., Tumour stem cells and drug resistance, Nat Rev Can, 5, 275-284 (2005)
[14] Diaz, LA Jr, The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers, Nature, 486, 537-540 (2012)
[15] Easwaran, H.; Tsai, HC; Baylin, SB, Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance, Mol Cell, 54, 716-727 (2014)
[16] Flavahan, WA; Gaskell, E.; Bernstein, BE, Epigenetic plasticity and the hallmarks of cancer, Science, 357, eaal2380 (2017) · doi:10.1126/science.aal2380
[17] Folguera-Blasco, N.; Pérez-Carrasco, R.; Cuyàs, E.; Menendez, JA; Alarcón, T., A multiscale model of epigenetic heterogeneity-driven cell fate decision-making, PLoS Comput Biol, 15, 4, e1006592 (2019)
[18] Gatenby, RA, Population ecology issues in tumor growth, Cancer Res, 51, 10, 2542-2547 (1991)
[19] Gatenby, R.; Brown, J., The evolution and ecology of resistance in cancer therapy, Cold Spring Harb Perspect Med, 8, a033415 (2018)
[20] Gerlee, P.; Nelander, S., The impact of phenotypic switching on glioblastoma growth and invasion, PLoS Computa Biol, 8, 6, e1002556 (2012)
[21] Goldman, A.; Majumder, B.; Dhawan, A.; Ravi, S.; Goldman, D.; Kohandel, M.; Sengupta, S., Temporally sequenced anticancer drugs overcome adaptive resistance by targeting a vulnerable chemotherapy-induced phenotypic transition, Nat Commun, 6, 1, 1-13 (2015)
[22] Gore, SD; Baylin, S.; Sugar, E.; Carraway, H.; Miller, CB; Carducci, M., Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms, Cancer Res, 66, 12, 6361-6369 (2006)
[23] Goss, PE; Chambers, AF, Does tumour dormancy offer a therapeutic target?, Nat Rev Cancer, 10, 12, 871-877 (2010)
[24] Gunnarsson, E.; De, S.; Leder, K.; Foo, J., Understanding the role of phenotypic switching in cancer drug resistance, J Theor Biol, 490, 110162 (2020) · Zbl 1430.92036
[25] Gupta, PB; Fillmore, CM; Jiang, G.; Shapira, SD; Tao, K.; Kuperwasser, C.; Lander, ES, Stochastic state transitions give rise to phenotypic equilibrium in populations of cancer cells, Cell, 146, 633-644 (2011)
[26] Hari, K.; Sabuwala, B.; Subramani, BV; La Porta, CA; Zapperi, S.; Font-Clos, F.; Jolly, MK, Identifying inhibitors of epithelial-mesenchymal plasticity using a network topology-based approach, NPJ Syst Biol Appl, 6, 1, 1-12 (2020)
[27] Huang, S., Reprogramming cell fates: reconciling rarity with robustness, Bioessays, 31, 546-560 (2009)
[28] Huang, S.; Kauffman, S., How to escape the cancer attractor: rationale and limitations of multi-target drugs, Sem Can Biol, 23, 270-278 (2013)
[29] Huang, S.; Ernberg, I.; Kauffman, S., Cancer attractors: a systems view of tumors from a gene network dynamics and developmental perspective, Sem Cell Develop Biol, 20, 869-876 (2009)
[30] Ishay-Ronen, D.; Diepenbruck, M.; Kalathur, RKR; Sugiyama, N.; Tiede, S.; Ivanek, R.; Christofori, G., Gain fat-lose metastasis: converting invasive breast cancer cells into adipocytes inhibits cancer metastasis, Cancer Cell, 35, 1, 17-32 (2019)
[31] Jolly, MK; Ware, KE; Gilja, S.; Somarelli, JA; Levine, H., EMT and MET: necessary or permissive for metastasis?, Mol Oncol, 11, 755-769 (2017)
[32] Jolly, MK; Kulkarni, P.; Weninger, K.; Orban, J.; Levine, H., Phenotypic plasticity, bet-hedging, and androgen independence in prostate cancer: role of non-genetic heterogeneity, Front Oncol, 8, 50 (2018)
[33] Jolly, MK; Mani, SA; Levine, H., Hybrid epithelial/mesenchymal phenotype (s): the “fittest” for metastasis?, Biochimi Biophys Acta (BBA)- Rev Cancer, 1870, 2, 151-157 (2018)
[34] Jopling, C.; Boue, S.; Belmonte, JCI, Dedifferentiation, transdifferentiation and reprogramming: three routes to regeneration, Nat Rev Mol Cell Biol, 12, 79-89 (2011)
[35] Jordan, CT; Guzman, ML; Noble, M., Cancer stem cells, New Engl J Med, 355, 1253-1261 (2006)
[36] Juergens, RA; Wrangle, J.; Vendetti, FP; Murphy, SC; Zhao, M.; Coleman, B., Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer, Cancer Discov, 1, 7, 598-607 (2011)
[37] Kalluri, R.; Weinberg, RA, The basics of epithelial-mesenchymal transition, J Clin Invest, 119, 6, 1420-1428 (2009)
[38] Kussell, E.; Leibler, S., Phenotypic diversity, population growth, and information in fluctuating environments, Science, 309, 2075-2078 (2005) · doi:10.1126/science.1114383
[39] Kuznetsov, VA; Makalkin, IA; Taylor, MA; Perelson, AS, Nonlinear dynamics of immunogenic tumors: parameter estimation and global bifurcation analysis, Bull Math Biol, 56, 2, 295-321 (1994) · Zbl 0789.92019
[40] Ledzewicz, U.; Schattler, H., Antiangiogenic therapy in cancer treatment as an optimal control problem, SIAM J Control Opt, 46, 3, 1052-1079 (2007) · Zbl 1357.49086
[41] Lerner, RA; Grover, RK; Zhang, H.; Xie, J.; Han, KH; Peng, Y.; Yea, K., Antibodies from combinatorial libraries use functional receptor pleiotropism to regulate cell fates, Q Rev Biophys, 48, 4, 389-394 (2015)
[42] Liau, BB; Sievers, C.; Donohue, LK; Gillespie, SM; Flavahan, WA; Miller, TE; Bernstein, BE, Adaptive chromatin remodeling drives glioblastoma stem cell plasticity and drug tolerance, Cell Stem Cell, 20, 2, 233-246 (2017)
[43] Margueron, R.; Reinberg, D., Chromatin structure and the inheritance of epigenetic information, Nat Rev Genet, 11, 285-296 (2010)
[44] Marusyk, A.; Almendro, V.; Polyak, K., Intra-tumor heterogeneity: a looking glass for cancer?, Nat Rev Can, 12, 323-334 (2012)
[45] Mathis, RA; Sokol, ES; Gupta, PB, Cancer cells exhibit clonal diversity in phenotypic plasticity, Open Biol, 7, 2, 160283 (2017)
[46] Neftel, C., An integrative model of cellular states, plasticity, and genetics for glioblastoma, Cell, 178, 835-849 (2019)
[47] Negrini, S.; Gorgoulis, VG; Halazonetis, TD, Genomic instability-an evolving hallmark of cancer, Nat Rev Mol Cell Biol, 11, 3, 220-228 (2010)
[48] Nowak MA (2006) Evolutionary dynamics: exploring the equations of life. Harvard University Press, p. 363 · Zbl 1115.92047
[49] O’connell, MP; Weeraratna, AT, Change is in the air: the hypoxic induction of phenotype switching in melanoma, J Inves Dermatol, 133, 2316-2317 (2013)
[50] Pacheco, JM; Santos, FC; Dingli, D., The ecology of cancer from an evolutionary game theory perspective, Interface Focus, 4, 4, 20140019 (2014)
[51] Piggliuci M (2001) Phenotypic plasticity: beyond nature and nurture. JHU Press, p. 328
[52] Pisco, AO; Brock, A.; Zhou, J.; Moor, A.; Mojtahedi, M.; Jackson, D.; Huang, S., Non-Darwinian dynamics in therapy-induced cancer drug resistance, Nat Commun, 4, 1, 1-11 (2013)
[53] Quintana, E., Efficient tumour formation by single human melanoma cells, Nature, 456, 593-598 (2008)
[54] Ramesh V, Brabletz T, Ceppi P. (2020) Targeting EMT in cancer with repurposed metabolic inhibitors. Trends Cancer
[55] Roose, T.; Chapman, SJ; Maini, PK, Mathematical models of avascular tumor growth, SIAM Rev, 49, 179-208 (2007) · Zbl 1117.93011
[56] Schop, D.; Janssen, FW; Borgart, E.; De Bruijn, JD; van Dijkhuizen-Radersma, R., Expansion of mesenchymal stem cells using a microcarrier- based cultivation system: growth and metabolism, J Tiss Eng Regen Med, 2, 2-3, 126-135 (2008)
[57] Shackleton, M.; Quintana, E.; Fearon, ER; Morrison, SJ, Heterogeneity in cancer: cancer stem cells versus clonal evolution, Cell, 138, 822-829 (2009)
[58] Sharma, SV, A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations, Cell, 141, 69-80 (2010)
[59] Sharma, P.; Hu-Lieskovan, S.; Wargo, JA; Ribas, A., Primary, adaptive, and acquired resistance to cancer immunotherapy, Cell, 168, 707-723 (2017)
[60] Smith, JM; Price, GR, The logic of animal conflict, Nature, 246, 5427, 15-18 (1973) · Zbl 1369.92134
[61] Solé, R.; Aguadé-Gorgorió, G., The ecology of cancer differentiation therapy, J Theor Biol, 511, 110552 (2021)
[62] Strobl MA, Gallaher J, West J, Robertson-Tessi M, Maini PK, Anderson A (2021) Spatial structure impacts adaptive therapy by shaping intra-tumoral competition. bioRxiv, 2020-11
[63] Su, Y.; Wei, W.; Robert, L.; Xue, M.; Tsoi, J.; Garcia-Diaz, A.; Heath, JR, Single-cell analysis resolves the cell state transition and signaling dynamics associated with melanoma drug-induced resistance, Proc Natl Acad Sci, 114, 52, 13679-13684 (2017)
[64] Sultan, SE, Phenotypic plasticity for plant development, function and life history, Trends Plant Sci, 5, 537-542 (2000) · doi:10.1016/S1360-1385(00)01797-0
[65] Swierniak, A.; Krzeslak, M.; Borys, D.; Kimmel, M., The role of interventions in the cancer evolution-an evolutionary games approach, Math Biosci Eng, 16, 1, 265-291 (2019) · Zbl 1497.92182
[66] Talpaz, M.; Silver, RT; Druker, BJ; Goldman, JM; Gambacorti-Passerini, C.; Guilhot, F.; Sawyers, CL, Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study Blood, J Am Soc Hematol, 99, 6, 1928-1937 (2002)
[67] Tracqui, P.; Cruywagen, GC; Woodward, DE; Bartoo, GT; Murray, JD; Alvord, EC Jr, A mathematical model of glioma growth: the effect of chemotherapy on spatio temporal growth, Cell Prolif, 28, 1, 17-31 (1995)
[68] Tripathi, S.; Chakraborty, P.; Levine, H.; Jolly, MK, A mechanism for epithelial-mesenchymal heterogeneity in a population of cancer cells, PLoS Comput Biol, 16, 2, e1007619 (2020)
[69] Waddington, CH, The strategy of genes (1957), London: Allen Unwin, London
[70] Wang, SC; Lin, XL; Li, J.; Zhang, TT; Wang, HY; Shi, JW; Xiao, D., MicroRNA-122 triggers mesenchymal-epithelial transition and suppresses hepatocellular carcinoma cell motility and invasion by targeting RhoA, PloS One, 9, 7, e101330 (2014)
[71] Weibull JW (1997) Evolutionary game theory. MIT press · Zbl 0879.90206
[72] Wilkie, KP; Hahnfeldt, P., Tumor-immune dynamics regulated in the microenvironment inform the transient nature of immune-induced tumor dormancy, Cancer Res, 73, 12, 3534-3544 (2013)
[73] Xie, J.; Zhang, H.; Yea, K.; Lerner, RA, Autocrine signaling based selection of combinatorial antibodies that transdifferentiate human stem cells, Proc Natl Acad Sci, 110, 20, 8099-8104 (2013)
[74] Yao, D.; Dai, C.; Peng, S., Mechanism of the mesenchymal-epithelial transition and its relationship with metastatic tumor formation, Mol Cancer Res, 9, 12, 1608-1620 (2011)
[75] Yeung, KT; Yang, J., Epithelial-mesenchymal transition in tumor metastasis, Mol Oncol, 11, 1, 28-39 (2017)
This reference list is based on information provided by the publisher or from digital mathematics libraries. Its items are heuristically matched to zbMATH identifiers and may contain data conversion errors. In some cases that data have been complemented/enhanced by data from zbMATH Open. This attempts to reflect the references listed in the original paper as accurately as possible without claiming completeness or a perfect matching.